Quantcast

Latest Pemetrexed Stories

2011-02-02 08:42:00

INDIANAPOLIS and PRINCETON, N.J., Feb. 2, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC). (Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO ) The randomized, multi-center, open-label Phase III trial,...

2011-01-27 00:02:58

This week, the Mesothelioma Applied Research Foundation, the leading organization funding mesothelioma research and providing patient services, announced the election of new Co-Chairs of its Board of Directors. Washington, DC (Vocus/PRWEB) January 26, 2011 The Mesothelioma Applied Research Foundation (Meso Foundation) announced today the election of Axel Hanauske, MD, PhD and Hanne Mintz as Co-Chairs of the Board of Directors of the Mesothelioma Applied Research Foundation. Dr. Hanauske...

2010-11-15 17:18:00

INDIANAPOLIS, Nov. 15, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that the trial on the validity of the compound patent for Alimta® (pemetrexed for injection) before the U.S. District Court for the District of Delaware ended this afternoon with a ruling from the court that judgment would be entered in Lilly's favor, thereby upholding the patent's validity. The decision came in the case of Eli Lilly and Company et al v. Teva Parenteral...

2010-10-11 14:04:33

Data presented today at the 35th European Society for Medical Oncology Congress Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared to previously reported outcomes for patients receiving chemotherapy alone. Dr. Miklos Pless, head of medical oncology at the Winterthur Hospital Cancer center in Switzerland, presented the data at the...

2010-10-11 06:30:00

INDIANAPOLIS, Oct. 11 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that its global Phase III trial evaluating ALIMTA® (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO)....

2010-10-04 08:00:00

BURLINGTON, Mass., Oct. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The Pharmacor 2010 findings from the topic entitled Non-Small-Cell Lung Cancer reveal that market growth...

2010-07-06 07:00:00

WALTHAM, Mass., July 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the non-small-cell lung cancer drug market in Brazil will reach $240 million by 2014. Factors fuelling this growth include a slight but steady annual increase in the number of incident cases, greater uptake of higher-priced brands of chemotherapy, targeted regimens and maintenance treatment (all in the advanced...

2010-05-20 17:00:00

INDIANAPOLIS, May 20 /PRNewswire-FirstCall/ -- Results of two Phase II trials evaluating ALIMTA® (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer (NSCLC) will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., on June 6, 2010. The standard of care for many patients with unresectable stage...

2010-05-17 07:00:00

INDIANAPOLIS, May 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company will unveil data from 57 studies at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 4 - 8, 2010, during which the company will present the latest research results on ALIMTA® (pemetrexed for injection) and GEMZAR® (gemcitabine HCl for injection), as well as ERBITUX® (cetuximab) with partners Bristol-Myers Squibb and...

2010-04-30 12:00:00

BROOMFIELD, Colo., April 30 /PRNewswire/ -- Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed oral therapy for advanced non-small cell lung cancer (NSCLC). Following treatment with erlotinib, patients...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related